Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry

Abstract Introduction Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germ...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Uwe Zeymer, Christiane Lober, Andreas Wolf, Frank Richard, Heinrich Schäfer, Jens Taggeselle, Hans-Joachim Kabitz, Roland Prondzinsky, Tim Süselbeck, the APAF-Investigators
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Adis, Springer Healthcare 2020-07-01
סדרה:	Cardiology and Therapy
נושאים:	Atrial fibrillation Apixaban Prospective registry Persistence
גישה מקוונת:	https://doi.org/10.1007/s40119-020-00188-1
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!